An Intervention Study in Healthy Infants Aged 0-6 Months With Probiotics Lacticaseibacillus Rhamnosus LRa05 (LRa05) and Bifidobacterium Animalis Subsp. Lactis BLa80 (BLa80) vs. Placebo, for Promoting Gut Microbiome Development.

Обзор

The probiotics Bifidobacterium animalis subsp. lactis BLa80 and Lacticaseibacillus rhamnosus LRa05 have potential to enhance infant health and development based on previous research conducted on human infants. Bifidobacterium animalis subsp. lactis BLa80 was isolated from healthy breast milk samples. Ten clinical studies have been conducted using this strain, including randomized, double-blind, placebo-controlled trials, involving over 700 clinical subjects, adults and children. Based on the results from these studies, functional benefits associated with ingestion of this probiotic include relief of diarrhea, relief of constipation, improved sleep quality, resistance to H. pylori infection, modulation of gut microbiota, promotion of infant growth and development, gestational diabetes management and emotional management. Lacticaseibacillus rhamnosus LRa05 was isolated from healthy baby faeces. Six clinical studies have been conducted, involving randomized, double-blind, placebo-controlled studies using this strain, involving over 500 clinical subjects. Based on the results from these studies, functional benefits associated with ingestion of this probiotic include relief of diarrhea, relief of eczema, resistance to H. pylori infection, modulation of gut microbiota, promotion of infant growth and development, and gestational diabetes management. This proposal describes a three-year collaboration with APC Microbiome Ireland, INFANT Research Centre and WeCare to conduct clinical studies to investigate the effects of probiotics (Bifidobacterium animalis subsp. lactis BLa80 and Lacticaseibacillus rhamnosus LRa050), compared to a placebo, on the growth of infants and toddlers and the development of their gut microbiota. The focus of this study is on infant growth and gut microbiota development in infants up to 6 months old.

Подробное описание

The primary aim is to describe the impact of supplementation with the probiotics LRa05 and BLa80 on the developing gut microbiota in infants aged 0-6 months. Gut microbiota structure will be analyzed following shotgun sequencing, including strain presence and persistence in the infant's gut during 0-6 months of age.

Secondary Objectives

1. To evaluate the impact of supplementation infant growth. Growth will be monitored by recording infant weight, length, and head circumference following the probiotic intervention. 2. To evaluate the safety of the probiotics and the incidence rate of allergies and abdominal disturbances (eczema, skin itching, bloating/abdominal distension, diarrhoea). 3. To detect human beta-defensin 2 (HBD-2) and Human Antimicrobial Peptide LL-37 (LL-37) in the faecal samples which aims to evaluate the impact of the two probiotic strains on the immune health of the infants following the probiotic intervention. 4. To detect the levels of short-chain fatty acids (SCFAs) in the faecal samples following the probiotic intervention.

Вмешательства

• Пищевая добавка Placebo (maltodextrin)
  This study will investigate the effects of probiotics (Bifidobacterium animalis subsp. lactis BLa80 or Lacticaseibacillus rhamnosus LRa05), versus a placebo (maltodextrin), on the growth of infants and the development of their gut microbiota. The primary focus is on infant growth and gut microbiota development in infants aged 0-6 months. Maltodextrin is white, powdery, almost flavourless starch that is used to mimic the probiotic powder.
• Пищевая добавка Probiotic
  This study will investigate the effects of probiotics Bifidobacterium animalis subsp. lactis BLa80, versus a placebo (maltodextrin), on the growth of infants and the development of their gut microbiota. The primary focus is on infant growth and gut microbiota development in infants aged 0-6 months.
• Пищевая добавка Probiotic
  This study will investigate the effects of probiotic Lacticaseibacillus rhamnosus LRa05, versus a placebo (maltodextrin), on the growth of infants and the development of their gut microbiota. The primary focus is on infant growth and gut microbiota development in infants aged 0-6 months.

Первичные конечные точки

• Primary Objective [Срок оценки: 18 months]

Вторичные конечные точки (8)

• Secondary Outcome Measure - Infant length [Срок оценки: 18 months]
• Secondary Outcome Measure - Infant Weight [Срок оценки: 18 months]
• Secondary Outcome Measure - Head circumference [Срок оценки: 18 months]
• Secondary Outcome Measure - SCFA Analysis [Срок оценки: 18 months]
• Secondary Outcome Measure - Peptide Analysis (HBD-2) [Срок оценки: 18 months]
• Secondary Outcome Measure - Peptide Analysis (LL-37) [Срок оценки: 18 months]
• Secondary Outcome Measure - Food Allergy Assessment (Eczema) [Срок оценки: 18 months]
• Secondary Outcome Measure - Food Allergy Assessment (Diarrhea) [Срок оценки: 18 months]

Критерии участия

Inclusion criteria Written (electronic) informed consent provided by parent to allow their infant to participate in the study.

No antibiotic use since birth. Infant not to be taking any medications. Infant not to be taking probiotics. Breastfed or formula fed until weaning. Infants born via c-section or vaginally. Healthy male and female infants.

Exclusion criteria Infant is older than 3 months at the time their first study visit (Baseline visit).

Infants who have a known diagnosis of inflammatory bowel disease or another medical condition.

Infants with complex medical or behavioural needs that would deem the infant unable to participate in the study.

Have a significant acute or chronic co-existing illness (cardiovascular, gastrointestinal, endocrinological, immunological, metabolic) or any condition which contraindicates entry to the study according to the investigator's judgement.

Infants who are receiving treatment involving experimental medications. Have a malignant disease or any concomitant end-stage organ disease. Infants born before 37 weeks of pregnancy.

Критерии приведены из реестра в оригинале (на английском). Окончательную оценку соответствия проводит исследовательский центр.

Здоровые добровольцы: Да

Дизайн исследования

Распределение

Рандомизированное

Модель

Параллельные группы

Маскирование

Четверное слепое

Основная цель

Фундаментальное исследование

Центры проведения

Ирландия · 1 центр

• University College Cork — Cork

Публикации

• Wu T, Zhang Y, Li W, Zhao Y, Long H, Muhindo EM, Liu R, Sui W, Li Q, Zhang M. Lactobacillus rhamnosus LRa05 Ameliorate Hyperglycemia through a Regulating Glucagon-Mediated Signaling Pathway and Gut Microbiota in Type 2 Diabetic Mice. J Agric Food Chem. 2021 Aug 11;69(31):8797-8806. doi: 10.1021/acs.jafc.1c02925. Epub 2021 Aug 2. PMID 34340304
• Niu Y, Li J, Qian H, Liang C, Shi X, Bu S. Evaluation of efficacy and safety of Lacticaseibacillus rhamnosus LRa05 in the eradication of Helicobacter pylori: a randomized, double-blind, placebo-controlled trial. Front Immunol. 2024 Aug 21;15:1450414. doi: 10.3389/fimmu.2024.1450414. eCollection 2024. PMID 39234246
• Chen K, Zeng K, Jin S, Ma Y, Cai L, Xu P, Nie Y, Luo L, Yu Q, Liu C. Lacticaseibacillus rhamnosus LRa05 in the treatment of acute diarrhea in children: a randomized controlled trial. Front Nutr. 2024 Nov 15;11:1479186. doi: 10.3389/fnut.2024.1479186. eCollection 2024. PMID 39619284
• Chen K, Jin S, Ma Y, Cai L, Xu P, Nie Y, Luo L, Yu Q, Shen Y, Zhou Z, Liu C. Adjudicative efficacy of Bifidobacterium animalis subsp. lactis BLa80 in treating acute diarrhea in children: a randomized, double-blinded, placebo-controlled study. Eur J Clin Nutr. 2024 Jun;78(6):501-508. doi: 10.1038/s41430-024-01428-6. Epub 2024 Mar 11. PMID 38467857

Идентификаторы

NCT: NCT07505329 · APC198

Первоисточники (государственные реестры)

• ClinicalTrials.gov (NIH, США)

Открыть это исследование на ClinicalTrials.gov ↗